Rethinking Menopausal Hormone Therapy After Risk-Reducing Salpingo-Oophorectomy in Women at High Risk for Breast Cancer

The authors investigate the use of menopausal hormone therapy (MHT) in women with hereditary breast and ovarian cancer syndrome who undergo risk-reducing salpingo-oophorectomy, particularly focusing on the potential benefits and safety of newer formulations like conjugated estrogen with bazedoxifene. They aim to address the suboptimal use of MHT in high-risk populations, such as BRCA1 and BRCA2 mutation carriers, and evaluate its impact on managing menopausal symptoms, maintaining bone health, and possibly reducing breast cancer risk. The findings could significantly influence menopause management guidelines for this unique group of women.